Related Experiment Video
Updated: Feb 20, 2026
09:29
Preparation and Implantation of Electrodes for Electrically Kindling VGAT-Cre Mice to Generate a Model for Temporal Lobe Epilepsy
Published on: August 17, 2021
2.9K
[Lacosamide (vimpat). Prospects for clinical application].
I G Rudakova1, P N Vlasov2, L V Lipatova3
1Vladimirsky Moscow Regional Research Clinical Institute, Moscow, Russia.
Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova
|October 21, 2017
Summary
Lacosamide (LCM) is an effective and well-tolerated treatment for focal epilepsy, showing benefits in long-term use, patient retention, and specific populations like the elderly. It offers advantages compared to other sodium channel blockers.
Area of Science:
- Neurology
- Pharmacology
- Clinical Medicine
Background:
- Focal epilepsy requires effective and tolerable antiepileptic drugs.
- Lacosamide (LCM) emerged as a significant option for epilepsy management.
- Understanding LCM's efficacy and tolerability is crucial for clinical practice.
Purpose of the Study:
- To review significant studies on lacosamide's efficacy and tolerability in focal epilepsy.
- To analyze LCM's performance in monotherapy and polytherapy, including long-term use.
- To compare LCM with other sodium channel blockers and assess its clinical utility.
Main Methods:
- Systematic review of key studies on lacosamide.
- Analysis of data on efficacy, tolerability, and treatment retention.
- Comparative assessment against other antiepileptic drugs.
Main Results:
- Lacosamide demonstrates significant efficacy and good tolerability in focal epilepsy.
- Positive outcomes observed in long-term use and treatment retention.
- LCM shows specific advantages in elderly patients and certain combinations.
Conclusions:
- Lacosamide is a valuable option for focal epilepsy treatment.
- Its favorable profile supports its continued use and consideration in treatment strategies.
- Further research can refine its role in comparison to other antiepileptic drugs.
Related Concept Videos
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
982
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
982
01:20Antiepileptic Drugs: Potassium Channel Activators
744
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
744
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
1.4K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.4K
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
2.7K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
2.7K
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
3.7K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
3.7K
01:14Antiepileptic Drugs: Glutamate Antagonists
1.0K
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
1.0K